Marinus Pharmaceuticals (MRNS) said Thursday that its phase 3 trial evaluating oral ganaxolone to treat seizures associated with tuberous sclerosis complex failed to meet the primary endpoint.
Shares slumped 81%, with intraday trading volume at over 37.1 million compared with a daily average of about 526,000.
Newmont (NEM) reported Q3 adjusted earnings late Wednesday that missed the average analyst estimate compiled by Capital IQ.
Shares retreated 14% as intraday trading volume jumped to over 27.2 million from a daily average of roughly 7.52 million.
Textron (TXT) reported fiscal Q3 adjusted earnings that lagged market expectations and its sales grew slower than forecast. The company also cut its adjusted EPS guidance for fiscal Q4.
Shares slid 6.8% as intraday trading volume climbed to more than 1.74 million from a daily average of about 903,000.
Price: 0.31, Change: -1.38, Percent Change: -81.89
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.